A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease

Pfeffer, Marc A., Burdmann, Emmanuel A., Chen, Chao-Yin, Cooper, Mark E., de Zeeuw, Dick, Eckardt, Kai-Uwe, Feyzi, Jan M., Ivanovich, Peter, Kewalramani, Reshma, Levey, Andrew S., Lewis, Eldrin F., McGill, Janet B., McMurray, John J.V., Parfrey, Patrick, Parving, Hans-Henrik, Remuzzi, Giuseppe, Singh, Ajay K., Solomon, Scott D., Toto, Robert·2009·New England Journal of Medicine
DOI 10.1056/nejmoa0907845

Cited by (1,000)

Items 801–900 of 1,000

  1. Anemia
    Gil Cunha De Santis · 2019 · Medicina (Ribeirão Preto)
  2. Effects of hypoxia-inducible factor prolyl hydroxylase inhibitors versus erythropoiesis-stimulating agents on iron metabolism and inflammation in patients undergoing dialysis: A systematic review and meta-analysis
    Qiyan Zheng, Pingna Zhang, Huisheng Yang, Yunling Geng, Jingyi Tang, Yi Kang, Airong Qi, Shunmin Li · 2023 · Heliyon
  3. Cardiorenal Syndrome: Challenges in Everyday Clinical Practice and Key Points towards a Better Management
    Theodora Georgopoulou, Ioannis Petrakis, Kleio Eleftheria Dermitzaki, Christos Pleros, Eleni Drosataki, Georgios Aletras, Emmanouil G Foukarakis, Eirini Lioudaki, Emmanuel S. Androulakis, Kostas Stylianou · 2023 · Journal of Clinical Medicine
  4. Renal Association Clinical Practice Guideline on Cardiovascular Disease in CKD
    Stephen Geoffrey Holt, David J.A. Goldsmith · 2011 · Nephron Clinical Practice
  5. Todayʼs Challenges in Pharmacovigilance
    Hans C. Ebbers, Aukje Kaija Mantel-Teeuwisse, Ellen H.M. Moors, Huub Schellekens, Hubert G. M. Leufkens · 2011 · Drug Safety
  6. Intravenous iron administration is associated with reduced platelet counts in patients with chronic kidney disease
    Adil Mohammad Hazara, Sunil Bhandari · 2014 · Journal of Clinical Pharmacy and Therapeutics
  7. Switching Patients with Non-Dialysis Chronic Kidney Disease from Oral Iron to Intravenous Ferric Carboxymaltose: Effects on Erythropoiesis-Stimulating Agent Requirements, Costs, Hemoglobin and Iron Status
    Jorge Eduardo Toblli, Federico Di Gennaro · 2015 · PLoS ONE
  8. Complications associated with erythropoietin‐stimulating agents in patients with metastatic breast cancer
    Mariana Chávez‐MacGregor, Hui Zhao, Shenying Fang, Tomasz P. Srokowski, Gabriel N. Hortobágyi, Sharon Hermes Giordano · 2011 · Cancer
  9. Whole‐blood viscosity increases significantly in small arteries and capillaries in hemodiafiltration. Does acute hemorheological change trigger cardiovascular risk events in hemodialysis patient?
    Bernard Canaud, Annie Rodriguez, Leïla Chénine, Marion Morena-Carrere, Isabelle Jaussent, Hélène Leray‐Moragues, A Picard, Jean‐Paul Cristol · 2010 · Hemodialysis International
  10. Prediction of the molecular mechanisms and potential therapeutic targets for diabetic nephropathy by bioinformatics methods
    Wanning Wang, Wenlong Zhang, Guangyu Zhou, Fuzhe Ma, Tao Sun, Sensen Su, Zhonggao Xu · 2016 · International Journal of Molecular Medicine
  11. Relationship between Hemoglobin Levels Corrected by Interdialytic Weight Gain and Mortality in Japanese Hemodialysis Patients: Miyazaki Dialysis Cohort Study
    Tatsunori Toida, Takashi Iwakiri, Yuji Sato, Hiroyuki Komatsu, Kazuo Kitamura, Shouichi Fujimoto · 2017 · PLoS ONE
  12. Safety of intravenous iron in hemodialysis patients
    Xiaojuan Li, Abhijit V. Kshirsagar, M. Alan Brookhart · 2017 · Hemodialysis International
  13. A phase Ib, open‐label, single arm study to assess the safety, pharmacokinetics, and impact on humoral sensitization of SANGUINATE infusion in patients with end‐stage renal disease
    Bassam G. Abu Jawdeh, E. Steve Woodle, Abbie D. Leino, Paul A. Brailey, Simon Tremblay, Tonya Dorst, Mouhamad H. Abdallah, Amit Govil, Daniel Byczkowski, Hemant K. Misra et al. · 2017 · Clinical Transplantation
  14. Individualized anemia management in a dialysis facility – long-term utility as a single-center quality improvement experience
    Adam E. Gawęda, Alfred A. Jacobs, George R. Aronoff, Michael E. Brier · 2018 · Clinical Nephrology
  15. Trajectories of Haemoglobin and incident stroke risk: a longitudinal cohort study
    Alimu Dayimu, Wendi Qian, Bingbing Fan, Chunxia Wang, Jiangbing Li, Shukang Wang, Xiaokang Ji, Guangshuai Zhou, Tao Zhang, Fuzhong Xue · 2019 · BMC Public Health
  16. DMOG, a Prolyl Hydroxylase Inhibitor, Increases Hemoglobin Levels without Exacerbating Hypertension and Renal Injury in Salt-Sensitive Hypertensive Rats
    Sota Kato, Teisuke Takahashi, Noriyuki Miyata, Richard J. Roman · 2019 · Journal of Pharmacology and Experimental Therapeutics
  17. Efficacy of quadruple treatment on different types of pre‐operative anaemia: secondary analysis of a randomised controlled trial
    Julian Rössler, Inga Hegemann, Felix Schoenrath, Burkhardt Seifert, Alexander Kaserer, Gabriela H. Spahn, Volkmar Falk, Donat Rudolf Spahn · 2020 · Anaesthesia
  18. Association of tubular solute clearances with the glomerular filtration rate and complications of chronic kidney disease: the Chronic Renal Insufficiency Cohort study
    Yan Chen, Leila R. Zelnick, Ke Wang, Ronit Katz, Andrew N. Hoofnagle, Jessica O. Becker, Chi‐yuan Hsu, Alan S. Go, Harold I. Feldman, Rupal C. Mehta et al. · 2020 · Nephrology Dialysis Transplantation
  19. Low serum iron is associated with anemia in CKD stage 1–4 patients with normal transferrin saturations
    Pei‐Hua Yu, Ming‐Yen Lin, Yi‐Wen Chiu, Jia‐Jung Lee, Shang‐Jyh Hwang, Chi‐Chih Hung, Hung‐Chun Chen · 2021 · Scientific Reports
  20. Cardiovascular risk in diabetic end-stage renal disease patients
    Angela Yee-Moon Wang · 2011 · Journal of Diabetes
  21. Predictors of anemia in a multi-ethnic chronic kidney disease population: a case–control study
    Bing Chang Vincent Lau, Kheng Yong Ong, Chun Wei Yap, Anantharaman Vathsala, Priscilla How · 2015 · SpringerPlus
  22. Impact of hemoglobin levels on renal and non-renal clinical outcomes differs by chronic kidney disease stages: the Gonryo study
    Tae Yamamoto, Mariko Miyazaki, Masaaki Nakayama, Gen Yamada, Masato Matsushima, Mistuhiro Sato, Toshinobu Sato, Yoshio Taguma, Hiroshi Satō, Sadayoshi Ito · 2015 · Clinical and Experimental Nephrology
  23. A randomised single-blind study to improve health-related quality of life by treating anaemia of chronic kidney disease with Aranesp® (darbepoetin alfa) in older people: STIMULATE
    Simon D. Roger, Sarbjit Vanita Jassal, Michael C. Woodward, Steven Soroka, Lawrence P. McMahon · 2013 · International Urology and Nephrology
  24. A Decade After the KDOQI CKD Guidelines: Impact on the Cardiovascular Disease–CKD Paradigm
    Daniel E. Weiner, Mark J. Sarnak · 2012 · American Journal of Kidney Diseases
  25. Goal-directed antihypertensive therapy: Lower may not always be better
    Edward John Filippone, Andrew Foy, Eric Newman · 2011 · Cleveland Clinic Journal of Medicine
  26. The effect of altitude on erythropoiesis-stimulating agent dose, hemoglobin level, and mortality in hemodialysis patients
    Scott P. Sibbel, Bradley J. Maroni, Steven M. Brunelli · 2016 · Journal of Nephrology
  27. Pre-End-Stage Renal Disease Hemoglobin Variability Predicts Post-End-Stage Renal Disease Mortality in Patients Transitioning to Dialysis
    Keiichi Sumida, Charles J. Diskin, Miklos Zsolt Molnar, Praveen Kumar Potukuchi, Fridtjof Thomas, Jun Lü, Connie M. Rhee, Elani Streja, Kunihiro Yamagata, Kamyar Kalantar‐Zadeh et al. · 2017 · American Journal of Nephrology
  28. Hyporesponsiveness to Darbepoetin Alfa in Patients With Heart Failure and Anemia in the RED-HF Study (Reduction of Events by Darbepoetin Alfa in Heart Failure)
    Peter van der Meer, Niels Grote Beverborg, Marc A. Pfeffer, Kurt A. Olson, Inder S. Anand, Berend Daan Westenbrink, John J.V. McMurray, Karl B Swedberg, James B. Young, Scott David Solomon et al. · 2018 · Circulation Heart Failure
  29. Time to Reconsider Evidence for Anaemia Treatment (TREAT) = Essential Safety Arguments (ESA)
    David J.A. Goldsmith, Adrian Constantin Covic · 2010 · Nephrology Dialysis Transplantation
  30. Recent advances in the management of hemodialysis patients: a focus on cardiovascular disease
    Kristen Jablonski, Michel Chonchol · 2014 · F1000Prime Reports
  31. Coronary Artery Disease in Chronic Kidney Disease: Need for a Heart–Kidney Team-Based Approach
    Gautam R. Shroff, Michelle D. Carlson, Roy O. Mathew · 2021 · European Cardiology Review
  32. The treatment of chronic anemia in heart failure: a global approach
    Vittorio Emanuele Bianchi, Stephan von Haehling · 2023 · Clinical Research in Cardiology
  33. Changes to the End-Stage Renal Disease Quality Incentive Program
    Steven N. Fishbane, Ilene J. Miller, John D. O. Wagner, Naveed N. Masani · 2012 · Kidney International
  34. Erythropoietin mimetic compound AGEM400(HES) binds to the same receptor as erythropoietin but displays a different spectrum of activities
    Claudia Keßler, Alexandra Greindl, Bettina Breuer, Udo Haberl, Andreas Rybka, Marco Emgenbroich, Hans‐Georg Frank, Andy J.G. Pötgens · 2011 · Cytokine
  35. Guía de práctica clínica de la ESC sobre diabetes, prediabetes y enfermedad cardiovascular, en colaboración con la European Association for the Study of Diabetes
    Lars Rydén, Grupo de Trabajo de la Sociedad Europea de Cardiología sobre diagnóstico y tratamiento de la cardiopatía isquémica estable, Peter J. Grant, Stefan D. Anker, Christian Berne, Francesco Cosentino, Nicolas Danchin, Christi Deaton, Javier Escaned, Hans Peter Hammes et al. · 2014 · Revista Española de Cardiología
  36. Association of higher erythropoiesis stimulating agent dose and mortality in children on dialysis
    Rachel M. Lestz, Barbara A. Fivush, Meredith A. Atkinson · 2014 · Pediatric Nephrology
  37. Mortality and Cardiovascular Morbidity Associated with Haemoglobin Levels: A Pooled Analysis of Randomised Controlled Trials
    Francesco Locatelli, Angel de Francisco, Gilbert Deray, Danilo Fliser, G. Armstrong, Frank Christopher Dougherty, Patricia B. Ehrhard · 2014 · Nephron Clinical Practice
  38. Managing advanced chronic kidney disease: A primary care guide
    Ankit Sakhuja, Jennifer Hyland, James F. Simon · 2014 · Cleveland Clinic Journal of Medicine
  39. Sickle Trait in African-American Hemodialysis Patients and Higher Erythropoiesis-Stimulating Agent Dose
    Vimal Kumar Derebail, Eduardo K. Lacson Jr., Abhijit V. Kshirsagar, Nigel S. Key, Susan L. Hogan, Raymond M. Hakim, Ann Mooney, Chinu M. Jani, Curtis Johnson, Yichun Hu et al. · 2014 · Journal of the American Society of Nephrology
  40. Oral or intravenous iron for anemia correction in chronic kidney disease?
    Tilman Bernhard Drüeke, Ziad A. Massy · 2015 · Kidney International
  41. The Safety of Erythropoiesis-Stimulating Agents for the Treatment of Anemia Resulting from Chronic Kidney Disease
    Nicolás Roberto Robles · 2016 · Clinical Drug Investigation
  42. End-of-Life Care in the Treatment of Advanced Heart Failure in the Elderly
    John Arthur McClung · 2012 · Cardiology in Review
  43. Associations of microvascular dysfunction with cardiovascular outcomes: The cardiac, endothelial function and arterial stiffness in ESRD (CERES) cohort
    Amrita Ayer, Claire Mills, Catherine Donovan, Robert H. Christenson, Peter Ganz, Ruth F. Dubin · 2019 · Hemodialysis International
  44. Correcting anemia and native vitamin D supplementation in kidney transplant recipients: a multicenter, 2 × 2 factorial, open‐label, randomized clinical trial
    Yoshitsugu Obi, Naotsugu Ichimaru, Yusuke Sakaguchi, Kazuhiro Iwadoh, Daisuke Ishii, Ken Sakai, Daiki Iwami, Hiroshi Harada, Keiichi Sumida, Akinari Sekine et al. · 2021 · Transplant International
  45. The clinical efficacy and safety of dapagliflozin in patients with diabetic nephropathy
    Ying Huang, Wen Lu, Hongyun Lu · 2022 · Diabetology & Metabolic Syndrome
  46. The anaemia control model: Does it help nephrologists in therapeutic decision-making in the management of anaemia?
    María Laura Bucalo, Carlo Barbieri, Susana Roca, Jasmine Ion Titapiccolo, Maria Soledad Ros Romero, Rosa Ramos, Mercedes Albaladejo Pérez, Diana Manzano, Flavio Mari, Manuel Molina · 2018 · Nefrología (English Edition)
  47. Erythropoietin molecules to treat acute ischemic stroke: a translational dilemma!
    Paul A. Lapchak · 2010 · Expert Opinion on Investigational Drugs
  48. Iron supplementation associates with low mortality in pre-dialyzed advanced chronic kidney disease patients receiving erythropoiesis-stimulating agents: a nationwide database analysis
    Ko‐Lin Kuo, Szu‐Chun Hung, Jia‐Sin Liu, Yu‐Kang Chang, Chih-Cheng Hsu, Der‐Cherng Tarng · 2015 · Nephrology Dialysis Transplantation
  49. Erythropoiesis-stimulating agent slows the progression of chronic kidney disease: a possibility of a direct action of erythropoietin
    Kazuhiko Tsuruya, Hisako Yoshida, Takaichi Suehiro, Kiichiro Fujisaki, Kosuke Masutani, Takanari Kitazono · 2016 · Renal Failure
  50. Characteristics, Cardiovascular Comorbidity and Medicines Management in Patients with Type 2 Diabetes and CKD: Results of the IRIDIEM Study
    Paul E. Stevens, Guntram Schernthaner, S. Raptis, Christoph Wanner, Armin W. Scherhag, Norbert Lameire · 2010 · Kidney & Blood Pressure Research
  51. Erythropoiesis-Stimulating Agents and Mortality
    Tilman Bernhard Drüeke, Ziad A. Massy · 2019 · Journal of the American Society of Nephrology
  52. The influence of Erythropoietin on platelet activation, thrombin generation and FVII/active FVII in patients with AMI
    Demetz, Gabriele, Laux, Magdalena, Scherhag, Armin, Hoekstra, Tiny, Suttorp, Marit M, Dekker, Friedo, Roest, Mark, Marcus-Kalish, Mira, Mittelman, Moshe, Ott, Ilka · 2014 · Thrombosis Journal
  53. Systematic Review of the Effects of Iron on Cardiovascular, Kidney, and Safety Outcomes in Patients With CKD
    Bernard Chan, Amanda Varghese, Sunil V. Badve, Roberto Pecoits‐Filho, Murilo Henrique Guedes, Clare Gabrielle Arnott, Rebecca Kozor, Emma O’Lone, Min Jun, Sradha S. Kotwal et al. · 2025 · Kidney International Reports
  54. Prevalence and Treatment Patterns of Anaemia in Individuals With Chronic Kidney Disease Across Asia: A Systematic Review and Meta‐Analysis
    Dana Kim, Joshua Y. Lee, Tadashi Toyama, Thaminda Liyanage, Mark Woodward, Kunihiro Matsushita, Lai Seong Hooi, Ming‐Yen Lin, Kunitoshi Iseki, Vivekanand Jha et al. · 2025 · Nephrology
  55. Erythropoietin in cardiac disease
    Vittoria Mastromarino, Beatrice Musumeci, Elena Conti, Giuliano Tocci, Massimo Volpe · 2013 · Journal of Cardiovascular Medicine
  56. Haemorragic and thromboembolic risk in CKD patients with non valvular atrial fibrillation: Do we need a novel risk score calculator?
    Maura Ravera, Elisabetta Bussalino, Ernesto Paoletti, Antonio Bellasi, Luca Di Lullo, Maria Fusaro · 2018 · International Journal of Cardiology
  57. Efficacy and Safety of Daprodustat for Anemia Therapy in Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis
    Qiyan Zheng, Ya‐Hui Wang, Huisheng Yang, Luying Sun, Xinwen Fu, Ruojun Wei, Yuning Liu, Wei Jing Liu · 2021 · Frontiers in Pharmacology
  58. Regional Variation in Hemoglobin Distribution Among Individuals With CKD: the ISN International Network of CKD Cohorts
    Mark Canney, Dilshani Induruwage, Mila Tang, Natália Alencar de Pinho, Lee Er, Yinshan Zhao, Ognjenka Djurdjev, Yo Han Ahn, Rouven Behnisch, Viviane Cálice-Silva et al. · 2023 · Kidney International Reports
  59. Sodium–Glucose Transporter 2 (SGLT2) Inhibitors and Iron Deficiency in Heart Failure and Chronic Kidney Disease: A Literature Review
    Maria Tziastoudi, Georgios Pissas, Spyridon Golfinopoulos, Georgios Filippidis, Periklis Dousdampanis, Theodoros Eleftheriadis, Ioannis Stefanidis · 2023 · Life
  60. Optimal hematocrit theory: a review
    Michal Šitina, Heiko Stark, Stefan Schuster · 2024 · Journal of Applied Physiology
  61. Managing dialysis patients who develop anemia caused by chronic kidney disease: focus on peginesatide
    Michael Hofmann, Valliant · 2013 · International Journal of Nanomedicine
  62. Summary of the Clinical Studies Reported in the Annual Scientific Sessions of the American Heart Association (Orlando, USA, November 14-18, 2009)
    Leopoldo Pérez de Isla, Antoni Bayés‐Genís, Juan Manuel Sanchís, Magda Heras · 2010 · Revista Española de Cardiología (English Edition)
  63. How Serious a Problem is Bleeding in Patients with Acute Coronary Syndromes?
    Usman Baber, Jason Ciril Kovacic, Annapoorna Subhash Kini, Samin K. Sharma, George Dangas, Roxana Mehran · 2011 · Current Cardiology Reports
  64. Targets, trends, excesses, and deficiencies: refocusing clinical investigation to improve patient outcomes
    Adeera Levin, William Lancashire, Robert Gordon Fassett · 2013 · Kidney International
  65. Optimising Treatment of End-Stage Renal Disease in the Elderly
    Albert John Power, Edwina Anne Brown · 2014 · Nephron Clinical Practice
  66. Iron repletion is associated with reduction in platelet counts in non-dialysis chronic kidney disease patients independent of erythropoiesis-stimulating agent use: a retrospective cohort study
    Lenar Yessayan, Jerry Yee, Gary Zasuwa, Stanley Frinak, Anatole Besarab · 2014 · BMC Nephrology
  67. New Options for Iron Supplementation in Maintenance Hemodialysis Patients
    Nosratola D. Vaziri, Kamyar Kalantar‐Zadeh, Jay B. Wish · 2015 · American Journal of Kidney Diseases
  68. Cardiorenal Syndrome in End-Stage Kidney Disease
    Kazuhiko Tsuruya, Masahiro Eriguchi, Shunsuke Yamada, Hideki Hirakata, Takanari Kitazono · 2015 · Blood Purification
  69. Serum Hepcidin and Iron Indices Affect Anemia Status Differently According to the Kidney Function of Non-Dialysis Chronic Kidney Disease Patients: Korean Cohort Study For Outcome in Patients with Chronic Kidney Disease (KNOW-CKD)
    Sung Woo Lee, Yeong Hoon Kim, Wookyung Chung, Sung Sup Park, Dong‐Wan Chae, Curie Ahn, Yong‐Soo Kim, Su Ah Sung · 2017 · Kidney & Blood Pressure Research
  70. Lessons from clinical trials with erythropoiesis-stimulating agents (ESAs)
    Tilman Bernhard Drüeke · 2018 · Renal Replacement Therapy
  71. Initial responsiveness to darbepoetin alfa and its contributing factors in non-dialysis chronic kidney disease patients in Japan
    Terumasa Hayashi, Hideki Kato, Kenichiro Tanabe, Masaomi Nangaku, Hideki Hirakata, Takashi Wada, Hiroshi Satō, Yasushi Yamazaki, Takao Masaki, Tatsuo Kagimura et al. · 2020 · Clinical and Experimental Nephrology
  72. Profile of Daprodustat in the Treatment of Renal Anemia Due to Chronic Kidney Disease
    Taisuke Ishii, Tetsuhiro Tanaka, Masaomi Nangaku · 2021 · Therapeutics and Clinical Risk Management
  73. Erythropoiesis stimulating agent recommendation model using recurrent neural networks for patient with kidney failure with replacement therapy
    Hae‐Ryong Yun, Gyubok Lee, Myeong Jun Jeon, Hyung Woo Kim, Young Su Joo, Hyoungnae Kim, Tae Ik Chang, Jung Tak Park, Seung Hyeok Han, Shin‐Wook Kang et al. · 2021 · Computers in Biology and Medicine
  74. Current Status of Renal Anemia Pharmacotherapy—What Can We Offer Today
    Bartłomiej Borawski, Jacek Stanisław Małyszko, Marlena Kwiatkowska, Jolanta Małyszko · 2021 · Journal of Clinical Medicine
  75. High-dose intravenous iron reduces myocardial infarction in patients on haemodialysis
    Mark Colquhoun Petrie, Pardeep S. Jhund, Eugene C. Connolly, Patrick Barry Mark, Michael Ross MacDonald, Michele Robertson, Stefan D. Anker, Sunil Bhandari, Ken Farrington, Philip A. Kalra et al. · 2021 · Cardiovascular Research
  76. Association of anemia and iron parameters with mortality among prevalent peritoneal dialysis patients in Taiwan: the AIM-PD study
    Ko‐Lin Kuo, Jia‐Sin Liu, Ming‐Huang Lin, Chih‐Cheng Hsu, Der‐Cherng Tarng, Szu‐Chun Hung, Ko‐Lin Kuo, Jia‐Sin Liu, Chih‐Cheng Hsu, Ming‐Huang Lin et al. · 2022 · Scientific Reports
  77. Management of Cardiovascular Diseases in Chronic Hemodialysis Patients
    Zhen Zhang, Yaqiong Wang · 2023 · Reviews in Cardiovascular Medicine
  78. Anemia and Iron Deficiency in Heart Failure
    Shanti Gunawardena, Mark E. Dunlap · 2012 · Current Heart Failure Reports
  79. Lack of association between anemia and renal disease progression in Chinese patients with type 2 diabetes
    Liubao Gu, Qinglin Lou, Haidi Wu, Xiaojun Ouyang, Rongwen Bian · 2015 · Journal of Diabetes Investigation
  80. Traditional and nontraditional risk factors as predictors of cerebrovascular events in patients with end stage renal disease
    Giovanni Luigi Tripepi, Francesco U.S. Mattace-Raso, Francesco Rapisarda, Benedetta Stancanelli, Lorenzo Malatino, Jacqueline C.M. Witteman, Carmine Zoccali, Francesca Mallamaci · 2010 · Journal of Hypertension
  81. Cost-effectiveness of continuous erythropoietin receptor activator in anemia
    Holger Schmid · 2014 · ClinicoEconomics and Outcomes Research
  82. Association of Lower Hemoglobin Level and Neuropathology in Community-Dwelling Older Persons
    Raj C. Shah, Julie A. Schneider, Sue E. Leurgans, David Alan Bennett · 2012 · Journal of Alzheimer s Disease
  83. A prospective observational study of early intervention with erythropoietin therapy and renal survival in non-dialysis chronic kidney disease patients with anemia: JET-STREAM Study
    JET-STREAM Study Group, Tadao Akizawa, Yoshiharu Tsubakihara, Hideki Hirakata, Yuzo Watanabe, Hiroki Hase, Shinichi Nishi, Tetsuya Babazono, Michiko Kumagai, Shingo Katakura et al. · 2016 · Clinical and Experimental Nephrology
  84. Mechanism of and Therapy for Kidney Fibrosis
    Akihiro Kuma, Masahito Tamura, Yutaka Otsuji · 2016 · Journal of UOEH
  85. Current and future chemical therapies for treating anaemia in chronic kidney disease
    Francesco Locatelli, Lucia Del Vecchio, Maria Carmen Luise · 2017 · Expert Opinion on Pharmacotherapy
  86. A new insight into the treatment of renal anemia with HIF stabilizer
    Satoru Kuriyama, Yukio Maruyama, Hirokazu Honda · 2020 · Renal Replacement Therapy
  87. Complications of Diabetes Mellitus
    Michael Brownlee, Lloyd Paul Aiello, Mark Emmanuel Cooper, Aaron I. Vinik, Richard W. Nesto, Andrew J.M. Boulton · 2011 · Elsevier eBooks
  88. Treatment of Anemia in Chronic Kidney Disease — Strategies Based on Evidence
    Philip A. Marsden · 2009 · New England Journal of Medicine
  89. Excess mortality attributable to chronic kidney disease. Results from the PIRP project
    Dino Gibertoni, Marcora Mandreoli, Paola Rucci, Maria Pia Fantini, Angelo Rigotti, Roberto Scarpioni, Antonio Santoro · 2015 · Journal of Nephrology
  90. Use of erythropoiesis-stimulating agents in children with chronic kidney disease: a systematic review
    Gordon Bruce, Peter Schulga, Ben C Reynolds · 2022 · Clinical Kidney Journal
  91. Safety Endpoints With Vadadustat Versus Darbepoetin Alfa in Patients With Non–Dialysis-Dependent CKD: A Post Hoc Regional Analysis of the PRO2TECT Randomized Clinical Trial of ESA-Naïve Patients
    Wolfgang C. Winkelmayer­, Susan Arnold, Steven K. Burke, Glenn Matthew Chertow, Kai‐Uwe Eckardt, Alan G. Jardine, Eldrin Foster Lewis, Wei Feng Luo, Kunihiro Matsushita, Peter Andrew McCullough et al. · 2023 · Kidney Medicine
  92. Implications of uremic cardiomyopathy for the practicing clinician: an educational review
    Hiroaki Hiraiwa, Daisuke Kasugai, Takahiro Okumura, Toyoaki Murohara · 2023 · Heart Failure Reviews
  93. Opportunities to improve the management of anemia in peritoneal dialysis patients: lessons from a national study in routine clinical practice
    José María Portolés, María Luisa Serrano Salazar, Olga González Peña, Sandra Gallego Domínguez, Manel Vera, Jara Caro, Alba Herreros García, María Antonia Munar Vila, María José Espigares Huete, R. Haridian Sosa Barrios et al. · 2023 · Clinical Kidney Journal
  94. Disproportionality Analysis on Hypothyroidism With Roxadustat Using the Japanese Adverse Drug Event Database
    Yasunobu Kouki, Naoto Okada, Kosuke Saga, Masakazu Ozaki, Atsuyuki Saisyo, Takashi Kitahara · 2023 · The Journal of Clinical Pharmacology
  95. Anemia Treatment, Hemoglobin Variability, and Clinical Events in Patients With Nondialysis-Dependent CKD in Japan
    Takahiro Kuragano, Suguru Okami, Sachiko Tanaka‐Mizuno, Hidetoshi Uenaka, Takeshi Kimura, Yosuke Ishida, Kanae Yoshikawa‐Ryan, Glen James, Takanori Hayasaki · 2023 · Kidney360
  96. The anaemia treatment journey of CKD patients: from epoetins to hypoxia-inducible factor-prolyl hydroxylase inhibitors
    Francesco Locatelli, Lucia Del Vecchio, Steve Elliott · 2023 · Clinical Kidney Journal
  97. Twenty years of participation of racialised groups in type 2 diabetes randomised clinical trials: a meta-epidemiological review
    Rabeeyah Ahmed, Russell J. de Souza, Vincent Li, Laura E. Banfield, Sonia Savitri Anand · 2024 · Diabetologia
  98. Cardiovascular and renal safety outcomes of hypoxia-inducible factor prolyl-hydroxylase inhibitor roxadustat for anemia patients with chronic kidney disease: a systematic review and meta-analysis
    Lei Tian, Mengdi Wang, Mengchao Liu, Yanyu Pang, Jingwen Zhao, Bingjie Zheng, Yutong Wang, Wenjing Zhao · 2024 · Renal Failure
  99. Prevalence, risk factors, and treatment of anemia in hospitalized older patients across geriatric and nephrological settings in Italy
    Luca Soraci, Antonio De Vincentis, Filippo Aucella, Paolo Fabbietti, Andrea Corsonello, Elena Arena, Francesco Aucella, Giuseppe Gatta, Raffaele Antonelli Incalzi · 2024 · Scientific Reports
  100. Effect of alternate night nocturnal home hemodialysis on anemia control in patients with end‐stage renal disease
    C.K.Y. Poon, Hon‐Lok Tang, Joseph H. S. Wong, Wai‐Ping Law, Chung-Man Lam, Ka‐Fai Yim, Au Cheuk, William Lee, Ka‐Foon Chau, Matthew K. L. Tong et al. · 2014 · Hemodialysis International